The circulating levels of adiponectin are downregulated in obesity and contribute to cardiometabolic diseases [28,29], in part due to its protective effect on pancreatic β-cells [30] and on the sympathetic nervous system response, thereby preventing cardiac sympathetic remodeling and cardiac remodeling from occurring upon myocardial infarction [31]. Here, ADIPOQ is linked to obesity disorder.